alanine has been researched along with Muscular Dystrophy, Duchenne in 2 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate disease progression and aging, we utilized young (1 month old) and old (21-25 months old) mdx and wild-type tongue muscles." | 1.91 | Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle. ( Chamberlain, JS; Ferretti, R; Lorena, MDSV; Matsumura, CY; Nagana Gowda, GA; Odom, GL; Santos, EKD, 2023) |
| "All patients with spinal muscular atrophy and congenital myopathy and one patient with Duchenne dystrophy, but none of six healthy subjects, developed hypoglycemia." | 1.32 | Patients with severe muscle wasting are prone to develop hypoglycemia during fasting. ( Hebert, A; Laub, M; Vissing, J; Zacho, M; Ørngreen, MC, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lorena, MDSV | 1 |
| Santos, EKD | 1 |
| Ferretti, R | 1 |
| Nagana Gowda, GA | 1 |
| Odom, GL | 1 |
| Chamberlain, JS | 1 |
| Matsumura, CY | 1 |
| Ørngreen, MC | 1 |
| Zacho, M | 1 |
| Hebert, A | 1 |
| Laub, M | 1 |
| Vissing, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics and Safety of Treatment With Paracetamol in Children and Adults With Spinal Muscular Atrophy and Cerebral Palsy[NCT03648658] | Phase 4 | 48 participants (Anticipated) | Interventional | 2019-02-18 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for alanine and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle.
Topics: Acetic Acid; Alanine; Animals; Creatine; Disease Progression; Glycerol; Isoleucine; Methionine; Mice | 2023 |
Patients with severe muscle wasting are prone to develop hypoglycemia during fasting.
Topics: Adult; Alanine; Blood Glucose; Body Weight; Fasting; Fatty Acids, Nonesterified; Female; Glycerol; H | 2003 |